雌激素受体α在绝经后骨质疏松中的研究进展及作用机制  

Research progress in the mechanism of estrogen receptor alpha in postmenopausal osteoporosis

作　　者：瞿霖 赵梦幻 王冬玉 宋蕾 周昆[1,2,3] QU Lin;ZHAO Menghuan;WANG Dongyu;SONG Lei;ZHOU Kun(Institute of Traditional Chinese Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617;Tianjin University of Traditional Chinese Medicine Drug Safety Evaluation Centre,Tianjin 301617;State Key Laboratory of Component-Based Chinese Medicine,Tianjin 301617,China)

机构地区：[1]天津中医药大学中医药研究院,天津301617 [2]天津中医药大学药物安全评价中心,天津301617 [3]组分中药国家重点实验室,天津301617

出　　处：《中国骨质疏松杂志》2024年第7期1021-1027,共7页Chinese Journal of Osteoporosis

基　　金：国家自然科学基金(81803797);天津市自然科学基金(18JCYBJC28700)。

摘　　要：绝经后骨质疏松(postmenopausal osteoporosis, PMOP)是亟需解决的公共健康问题。患者雌激素减少,雌激素受体(estrogen receptor α,ERα)表达水平下降,成骨细胞功能下降,破骨细胞活性增强,骨代谢偶联失衡。ERα在PMOP的发生发展中具有重要作用,笔者从PubMed、Web of Science和中国知网检索近10年(2013-2023年)骨质疏松研究领域的文献,总结归纳ERα在骨髓间充质干细胞、成骨细胞祖细胞、成骨细胞前体细胞、成熟成骨细胞、破骨细胞和骨细胞中的作用,并以能显著改善PMOP的黄酮类成分淫羊藿苷为例阐述基于ERα的抗PMOP相关机制。Postmenopausal osteoporosis(PMOP)is a public health issue that needs to be addressed urgently.Patients are with decreased estrogen level,decreased estrogen receptorα(ERα)expression level,decreased osteoblast function,increased osteoclast activity,and imbalance of bone metabolic.ERαplays an important role in the occurrence and development of PMOP.In this paper,literature in the field of osteoporosis in recent ten years(2013-2023)are retrieved from PubMed,Web of Science,and CNKI.The role of ERαin bone mesenchymal stem cells,osteoblast progenitors,osteoblast progenitors,mature osteoblasts,osteoclasts,and osteocytes were summarized.The relevant anti-PMOP mechanism of ERαis expounded based on an example of icariin,a flavonoid component that significantly relieves PMOP.

关 键 词：绝经后骨质疏松 雌激素受体Α 成骨细胞 破骨细胞 

分 类 号：R589.5[医药卫生—内分泌]